Healthcare's Next Growth Drivers: M&A, Innovation and AI

Healthcare growth should be driven by resilient strategic M&A, innovation in oncology and obesity, and AI-enabled productivity gains despite policy uncertainty and patent expirations.

• Annualized global announced healthcare M&A volume has reached approximately $4.7 trillion, versus a $3.2 trillion average for 2016–2025, while transactions valued at $10 billion or more are up 57% year to date.
• Strategic acquirers are driving activity, with biopharma representing roughly 70% of healthcare deal activity as companies seek pipeline growth ahead of significant patent expirations later this decade.
• Biotech financing and M&A are benefiting from differentiated clinical data, strong drug launches and a broader buyer universe, while healthcare services M&A could reaccelerate over the next 12 to 18 months.
• Oncology opportunities include T-cell priming beyond melanoma into lung, bladder and renal cancers, while liquid biopsies may approach an adoption inflection point as reimbursement pathways mature.
• Obesity-treatment utilization remains in the single digits among potentially eligible patients, leaving room for broader adoption and for oral and longer-duration formulations to improve convenience and adherence.
• AI is being applied to molecular design, regulatory submissions, commercial engagement and post-discharge follow-up, with some regulatory workflows shortened from months to weeks.

Takeaway: Investors should focus on strategic buyers and differentiated assets in biopharma, monitor potential healthcare-services deal activity, and assess AI primarily through measurable productivity and workflow benefits rather than speculative scientific breakthroughs.